Five-year Local Control in a Phase II Study of Hypofractionated Intensity Modulated Radiation Therapy With an Incorporated Boost for Early Stage Breast Cancer

被引:33
|
作者
Freedman, Gary M. [1 ]
Anderson, Penny R. [2 ]
Bleicher, Richard J. [4 ]
Litwin, Samuel [3 ]
Li, Tianyu [3 ]
Swaby, Ramona F. [5 ]
Ma, Chang-Ming Charlie [2 ]
Li, Jinsheng [2 ]
Sigurdson, Elin R. [4 ]
Watkins-Bruner, Deborah [6 ]
Morrow, Monica [7 ]
Goldstein, Lori J. [5 ]
机构
[1] Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA
[2] Fox Chase Canc Ctr, Dept Radiat Oncol, Philadelphia, PA 19111 USA
[3] Fox Chase Canc Ctr, Dept Biostat, Philadelphia, PA 19111 USA
[4] Fox Chase Canc Ctr, Dept Surg Oncol, Philadelphia, PA 19111 USA
[5] Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA
[6] Emory Univ, Sch Nursing, Atlanta, GA 30322 USA
[7] Mem Sloan Kettering Canc Ctr, Dept Surg Oncol, New York, NY 10021 USA
关键词
Breast boost; Breast cancer; Hypofractionation; IMRT; Radiation therapy; CONSERVING SURGICAL-PROCEDURES; QUALITY-OF-LIFE; RANDOMIZED-TRIAL; RADIOTHERAPY; WOMEN; IRRADIATION; SURGERY; FORM; RT;
D O I
10.1016/j.ijrobp.2012.01.091
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Conventional radiation fractionation of 1.8-2 Gy per day for early stage breast cancer requires daily treatment for 6-7 weeks. We report the 5-year results of a phase II study of intensity modulated radiation therapy (IMRT), hypofractionation, and incorporated boost that shortened treatment time to 4 weeks. Methods and Materials: The study design was phase II with a planned accrual of 75 patients. Eligibility included patients aged >= 18 years, Tis-T2, stage 0-II, and breast conservation. Photon IMRT and an incorporated boost was used, and the whole breast received 2.25 Gy per fraction for a total of 45 Gy, and the tumor bed received 2.8 Gy per fraction for a total of 56 Gy in 20 treatments over 4 weeks. Patients were followed every 6 months for 5 years. Results: Seventy-five patients were treated from December 2003 to November 2005. The median follow-up was 69 months. Median age was 52 years (range, 31-81). Median tumor size was 1.4 cm (range, 0.1-3.5). Eighty percent of tumors were node negative; 93% of patients had negative margins, and 7% of patients had close (>0 and <2 mm) margins; 76% of cancers were invasive ductal type: 15% were ductal carcinoma in situ, 5% were lobular, and 4% were other histology types. Twenty-nine percent of patients 29% had grade 3 carcinoma, and 20% of patients had extensive in situ carcinoma; 11% of patients received chemotherapy, 36% received endocrine therapy, 33% received both, and 20% received neither. There were 3 instances of local recurrence for a 5-year actuarial rate of 2.7%. Conclusions: This 4-week course of hypofractionated radiation with incorporated boost was associated with excellent local control, comparable to historical results of 6-7 weeks of conventional whole-breast fractionation with sequential boost. (C) 2012 Elsevier Inc.
引用
收藏
页码:888 / 893
页数:6
相关论文
共 50 条
  • [1] Five-year Results of a Phase II Study of Hypofractionated IMRT with an Incorporated Boost for Breast Cancer
    Freedman, G. M.
    Anderson, P.
    Litwin, S.
    Swaby, R.
    Nicolaou, N.
    Sigurdson, E.
    Ma, C.
    Watkins-Bruner, D.
    Morrow, M.
    Goldstein, L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S77 - S77
  • [2] A phase II study of four-week radiation for breast cancer using hypofractionated intensity modulated radiation therapy (IMRT) with an incorporated boost
    Freedman, G. M.
    Anderson, P.
    Goldstein, L.
    Litwin, S.
    Li, J.
    Watkins-Bruner, D.
    Nicolaou, N.
    Swaby, R.
    Sigurdson, E.
    Morrow, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (03): : S176 - S176
  • [3] Moderately Hypofractionated Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost for Prostate Cancer: Five-Year Toxicity Results From a Prospective Phase I/II Trial
    Ricco, Anthony
    Mukhopadhyay, Nitai
    Deng, Xiaoyan
    Holdford, Diane
    Skinner, Vicki
    Saraiya, Siddharth
    Moghanaki, Drew
    Anscher, Mitchell S.
    Chang, Michael G.
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [4] Four-week course of radiation for breast cancer using hypofractionated intensity modulated radiation therapy with an incorporated boost
    Freedman, Gary M.
    Anderson, Penny R.
    Goldstein, Lori J.
    Ma, Chang-Ming
    Li, Jinsheng
    Swaby, Ramona F.
    Litwin, Samuel
    Watkins-Bruner, Deborah
    Sigurdson, Elin R.
    Morrow, Monica
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 68 (02): : 347 - 353
  • [5] Five-year Results of Whole Breast Intensity Modulated Radiation Therapy for the Treatment of Early Stage Breast Cancer: The Fox Chase Cancer Center Experience
    Keller, Lanea M. M.
    Sopka, Dennis M.
    Li, Tianyu
    Klayton, Tracy
    Li, Jinsheng
    Anderson, Penny R.
    Bleicher, Richard J.
    Sigurdson, Elin R.
    Freedman, Gary M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (04): : 881 - 887
  • [6] Intensity modulated radiation therapy with stereotactic body radiation therapy boost for unfavorable prostate cancer: five-year outcomes
    Carrasquilla, Michael
    Sholklapper, Tamir
    Pepin, Abigail N.
    Hodgins, Nicole
    Lei, Siyuan
    Rashid, Abdul
    Danner, Malika
    Zwart, Alan
    Bolanos, Grecia
    Ayoob, Marilyn
    Yung, Thomas
    Aghdam, Nima
    Collins, Brian
    Suy, Simeng
    Kumar, Deepak
    Hankins, Ryan
    Kowalczyk, Keith
    Dawson, Nancy
    Collins, Sean
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [7] Concomitant Hypofractionated Intensity Modulated Radiation Therapy Boost For Localized High-Risk Prostate Cancer: Five-Year Results of a Prospective Trial
    Cheung, P.
    Morton, G.
    Szumacher, E.
    Danjoux, C.
    Chung, H. T.
    Vesprini, D.
    Choo, C. R.
    Chu, W.
    Deabreu, A.
    Mamedov, A.
    Zhang, L.
    Loblaw, D. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : S33 - S33
  • [8] Five-Year Report of the Institutional Phase II Trial of Once Weekly Hypofractionated Whole Breast Irradiation for Early-Stage Breast Cancer
    Reshko, L. B.
    Pan, J.
    Rai, S. N.
    Ajkay, N.
    Dragun, A. E.
    Roberts, T. E.
    Riley, E.
    Quillo, A.
    Scoggins, C.
    McMasters, K. M.
    Eldredge-Hindy, H. B.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E210 - E210
  • [9] Long-term Toxicity and Outcomes of Hypofractionated Radiation Therapy With an Incorporated Boost for Early-Stage Breast Cancer
    Wang, L.
    Murphy, C. T.
    Handorf, E.
    Freedman, G. M.
    Johnson, M. E.
    Shaikh, T.
    Hayes, S. B.
    Bleicher, R. J.
    Goldstein, L.
    Anderson, P. R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : S59 - S60
  • [10] Five-year results from a phase I/II study of moderately hypofractionated intensity-modulated radiation therapy (IMRT) for localized prostate cancer including simultaneously integrated boost and pelvic lymph node (LN) coverage
    Ricco, Anthony
    Mukhopadhyay, Nitai
    Holdford, Diane
    Skinner, Vicki
    Saraiya, Siddharth
    Moghanaki, Drew
    Anscher, Mitchell Steven
    Chang, Michael G.
    Deng, Xiaoyan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)